Money Concepts Capital Corp Purchases 2,286 Shares of Johnson & Johnson (NYSE:JNJ)

Money Concepts Capital Corp increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,968 shares of the company's stock after acquiring an additional 2,286 shares during the quarter. Money Concepts Capital Corp's holdings in Johnson & Johnson were worth $7,292,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $29,000. Conquis Financial LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at $33,000. Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson in the fourth quarter worth $36,000. Finally, Highline Wealth Partners LLC raised its holdings in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded up $3.06 during trading hours on Tuesday, reaching $155.81. The stock had a trading volume of 10,894,899 shares, compared to its average volume of 8,045,918. The company has a market cap of $374.89 billion, a price-to-earnings ratio of 17.33, a PEG ratio of 2.31 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The business's fifty day moving average is $153.66 and its two-hundred day moving average is $153.86. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.34%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Wall Street Zen raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their target price for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Morgan Stanley upped their price target on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 16th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.